Full Press Release Details
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761.
IMMP
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Key Takeaway: Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Price reaction · baseline $2.26 (2024-04-17 close) · hit after-hours · 1 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-2.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)